By Terri Jo Neff |
The Arizona Chamber of Commerce and Industry is hoping the U.S. House of Representatives takes a hard look at H.R. 5376, which was formerly known as the Build Back Better Act until being recently rechristened as the Inflation Reduction Act of 2022.
“Arizona job creators oppose the vast majority of the provisions in this bill,” Chamber CEO Danny Seiden said Sunday after the U.S. Senate passed the legislation on party lines. “This bill will not reduce inflation and it will not make the U.S. economy more competitive. Renaming a massive tax and spending bill the Inflation Reduction Act does not improve it.”
Seiden says Sen. Kyrsten Sinema met with Arizona business stakeholders to hear their concerns and did help blunt some of the more harmful provisions, especially those which impact manufacturing businesses already doubly hit by inflation and supply chain disruptions
He also acknowledged there are a few beneficial elements of H.R. 5376 such as provisions which encourage continued business investment and provide significant drought resiliency funding to promote a water secure future.
But despite some of “positive aspects,” Seiden insists H.R. 5376 leaves much to be desired. Which is why he and other state business leaders are calling on Arizona’s nine Representatives to take a closer look at the bill in advance of an expected Aug. 12 vote.
“With the bill headed to the House, we would encourage the Arizona delegation to consider the legislation’s negative effect on Arizona jobs,” Seiden said, adding that that renaming the unpopular Build Back Better Act does not improve the fact the legislation is a massive tax and spending bill.
The legislation is estimated to raise $740 billion in additional revenue from new taxes as well as more enforcement of existing tax laws. It also authorizes $430 billion in new spending, although a more thorough analysis by the Congressional Budget Office has not been completed.
One thing the CBO already knows, U.S. Senator Bernie Sanders said on the Senate Floor, is that what he labeled the “so-called” Inflation Reduction Act will have “a minimal impact on inflation.”
The CEO of the National Association of Manufacturers also expressed disappointment with H.R. 5376. According to Jay Timmons, the Inflation Reduction Act will stifle manufacturing investment in America, undermining the very businesses which kept America’s economy afloat during the COVID-19 pandemic.
“To be sure, (the bill) was worse before Sen. Sinema worked to protect some areas of manufacturing investment,” Timmons said. “But the final bill is still bad policy and will harm our ability to compete in a global economy.”
Also speaking out against H.R. 5376 is the Pharmaceutical Research and Manufacturers of America, whose members will be directly impacted by Medicare drug price controls included in the legislation.
“They say they’re fighting inflation, but the Biden administration’s own data show that prescription medicines are not fueling inflation,” said PhRMA CEO Stephen Ubl. “And they say the bill won’t harm innovation, but various experts, biotech investors and patient advocates agree that this bill will lead to fewer new cures and treatments for patients battling cancer, Alzheimer’s and other diseases.”